CMLase (engineered CML-degrading enzyme)

What it is

CMLase is a lab-engineered enzyme designed to reverse a specific form of age-related protein damage. Over decades, sugars react with proteins to leave behind stable byproducts called advanced glycation end products (AGEs); the most abundant of these in aging tissue is Nε-carboxymethyl-lysine (CML), which had long been considered chemically irreversible.S1 Researchers at Revel Pharmaceuticals, with collaborators, started from a bacterial glycine oxidase scaffold and used computational structure mining (screening databases including AlphaFold-predicted structures) followed by directed evolution across more than 500 million variants to build an enzyme that oxidizes CML and restores the original lysine residue.S1S2 It is an engineered enzyme, not a peptide and not a supplement.S1

What the study showed

In the peer-reviewed report, CMLase reduced CML on a panel of model proteins in vitro (including collagen, hemoglobin, casein, and a retinal protein extract), and site-level proteomics on one model protein found reduced CML at 30 of 33 modified sites, with seven sites cut by more than 90%.S1 Applied to tissue from elderly donors, it reduced CML by more than 70% in arterial tissue and more than 55% in the epidermal and dermal layers of skin, bringing skin CML staining below the level seen in 31-year-old skin.S1 The authors frame this as proof-of-concept that a damage type previously deemed permanent can be enzymatically repaired.S1

What it is not

The results are ex vivo — enzyme applied to homogenized protein or thin, fixed tissue sections in the lab, where the target is maximally accessible. The authors explicitly note that whether chemical CML removal translates to restored tissue function or to silencing harmful RAGE signaling in a living body remains to be determined, and that penetrating the dense extracellular matrix of intact, living organs still needs to be evaluated.S1 There is no in vivo data (animal or human), no clinical trial, and no demonstration that CMLase works as a topical or absorbed treatment.S1 "Reversing skin age" here means lower CML staining in donated tissue, not a proven cosmetic or health outcome.S1

How it is being framed publicly

Popular and investor commentary has described the finding as a near-term anti-aging skincare or "reverse aging cream" breakthrough with a very large market.S3 That framing runs ahead of the evidence: the study is an early proof-of-concept in tissue samples, and independent reporting has paired the result with the same translational caveats the authors raise.S1S3 There is no marketed CMLase product, and none of the market projections are established outcomes.S3

Regulatory status (US)

CMLase is not an FDA-approved drug, not a compounded preparation, and not available as a consumer product or supplement.S1S2 It is a research-stage enzyme reported in the primary literature; any human use would require preclinical safety work and FDA authorization to begin clinical trials.S1

Safety

No human or animal safety data exist for CMLase.S1 The authors flag that its bacterial origin necessitates rigorous evaluation of immunogenicity, potentially requiring de-immunization or immunomodulation strategies for repeat dosing, and note that the reaction byproducts (hydrogen peroxide and glyoxylate) are normally cleared by the body but were only reasoned about, not tested in vivo.S1

What to watch

The near-term questions are whether Revel and collaborators publish in vivo data, identify a delivery approach that reaches CML inside living tissue, and name a development candidate; no company timeline for a human product has been established in the primary literature.S1S2